STATEMENT: FDA Decision on Mifepristone Will Improve Patients’ Access to Needed Health Care
Washington, D.C. — Today, the U.S. Food and Drug Administration (FDA) completed its review of mifepristone through the Risk Evaluation and Mitigation Strategy (REMS) program. As part of its decision, the FDA lifted the in-person dispensing restriction on mifepristone, a medication commonly used for early abortion and miscarriage care. Maggie Jo Buchanan, senior director for the Women’s Initiative at the Center for American Progress, released the following statement:
The FDA’s decision on mifepristone is a critical step to ensure patients are able to access needed, time-sensitive health care in a safe setting of their choice. While welcome news, there is much more that needs to be done—including, but certainly not limited to, when it comes to medication for abortion and miscarriage care—to ensure all people, regardless of their location or income, can access the care that they need. Regrettably, radical politicians across the country have already attempted to preempt this decision by passing bills to disrupt patients’ access to essential treatment.
Without proactive work at both the federal and state level, people in many states will continue to face significant barriers to accessing the care that they need—a fact made all the more clear in light of the U.S. Supreme Court’s seeming openness to upending precedents established in Roe v. Wade and affirmed in Casey v. Planned Parenthood.
For more information or to speak with an expert, please contact Colin Seeberger at email@example.com or 202.741.6292.